Characteristics of strains of BiorenalTM

Streptococcus thermophilus, Lactobacillus acidophilus and Bifidobacterium longum

  • Targets and metabolizes various nitrogenous wastes that diffuse from the bloodstream into the bowel.
  • Uric acid, creatinine, indoles, phenols, nitrosamines are the nitrogenous wastes mainly targetted.

Bacillus subtilis HU58®

  • Facilitates the reduction of ammonia in the gut as it does not influence proteolytic fermentation thus associated with reduced ammonia formation.
  • Also lowers serum creatinine and urea levels.

Fructo-oligosaccharides

  • A prebiotic or fibre component, used as a source of dietary fibre promotes growth of Bifidobacteria and inhibits pathogenic Clostridia.
  • It decreases faecal pH, increases faecal or colonic organic acids and decreases production of nitrogenous end products in urine and stools.
  • Fermented in the caecum and the colon, it produces Short Chain Fatty Acids (SCFA), mainly acetate, propionate and butyrate, which is used mainly as an energy source by the colonocytes.

Vitamin K2-7

  • Abrogates vascular calcification and thus prevents cardiovasular events in CKD patients.
  • Compared to other forms and subtypes, vitamin K2-7 exhibits the highest efficacy in humans due to its better bioavailability and longer half-life.

Composition and dose of BiorenalTM

Benefits of Biorenal TM

Benefits in chronic kidney disease

  • Combination of probiotics - S. thermophilus, L. acidophilus and B. longum have demonstrated significant efficacy in CKD as evidenced by reductions in the accumulation of circulating uremic toxins.
  • Bacillus subtilis HU58® renders an advantage to CKD patients by increasing saccharolytic fermentation with no effects on the proteolytic fermentation. It helps in reduction of ammonia in the gut as it does not influence proteolytic fermentation thus associated with reduced ammonia formation.
  • A number of in vivo studies have also shown that ingestion of fructo-oligosaccharide selectively stimulates the growth of Bifidobacteria and inhibited the growth of Clostridia.
  • A double-blind, placebo-controlled, randomized demonstrated that FOS resulted in a reduction in the uremic toxins mainly serum total and free PCS (p-cresyl sulfate) in non-diabetic CKD patients.
  • Vascular calcification, frequently observed in patients with all stages of CKD, is associated with increased risk of cardiovascular mortality. There is a growing body of evidence suggesting that vitamin K2 supplementation abrogates vascular calcification and thus development of cardiovascular diseases (CVD) in CKD patients through activation of MGP.

Copyright © 2024 Synergia Life Sciences Pvt. Ltd.